These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 35803202)
1. Editorial overview: Anti-viral strategies: Human antibody immune response and antibody-based therapy against viruses. Wang Q; Huang Z Curr Opin Virol; 2022 Aug; 55():101247. PubMed ID: 35803202 [No Abstract] [Full Text] [Related]
2. Fcγ Receptors Contribute to the Antiviral Properties of Influenza Virus Neuraminidase-Specific Antibodies. Job ER; Ysenbaert T; Smet A; Van Hecke A; Meuris L; Kleanthous H; Saelens X; Vogel TU mBio; 2019 Oct; 10(5):. PubMed ID: 31641082 [TBL] [Abstract][Full Text] [Related]
3. Antiviral Monoclonal Antibodies: Can They Be More Than Simple Neutralizing Agents? Pelegrin M; Naranjo-Gomez M; Piechaczyk M Trends Microbiol; 2015 Oct; 23(10):653-665. PubMed ID: 26433697 [TBL] [Abstract][Full Text] [Related]
4. A Novel Mechanism Underlying Antiviral Activity of an Influenza Virus M2-Specific Antibody. Manzoor R; Eguchi N; Yoshida R; Ozaki H; Kondoh T; Okuya K; Miyamoto H; Takada A J Virol; 2020 Dec; 95(1):. PubMed ID: 33055251 [TBL] [Abstract][Full Text] [Related]
5. Innate antiviral immune signaling, viral evasion and modulation by HIV-1. Rustagi A; Gale M J Mol Biol; 2014 Mar; 426(6):1161-77. PubMed ID: 24326250 [TBL] [Abstract][Full Text] [Related]
6. T-bodies as antiviral agents. Bitton N; Debre P; Eshhar Z; Gorochov G Curr Top Microbiol Immunol; 2001; 260():271-300. PubMed ID: 11443878 [No Abstract] [Full Text] [Related]
7. Serum strain-specific or cross-reactive neuraminidase inhibiting antibodies against pandemic А/California/07/2009(H1N1) influenza in healthy volunteers. Desheva YA; Smolonogina TA; Donina SA; Rudenko LG BMC Res Notes; 2015 Apr; 8():136. PubMed ID: 25889924 [TBL] [Abstract][Full Text] [Related]
8. Human Monoclonal Antibody 81.39a Effectively Neutralizes Emerging Influenza A Viruses of Group 1 and 2 Hemagglutinins. Marjuki H; Mishin VP; Chai N; Tan MW; Newton EM; Tegeris J; Erlandson K; Willis M; Jones J; Davis T; Stevens J; Gubareva LV J Virol; 2016 Dec; 90(23):10446-10458. PubMed ID: 27630240 [TBL] [Abstract][Full Text] [Related]
9. Human β-defensin 2 plays a regulatory role in innate antiviral immunity and is capable of potentiating the induction of antigen-specific immunity. Kim J; Yang YL; Jang SH; Jang YS Virol J; 2018 Aug; 15(1):124. PubMed ID: 30089512 [TBL] [Abstract][Full Text] [Related]
10. [Antiviral humanized and human monoclonal antibodies]. Lashkevich VA Vopr Virusol; 2011; 56(5):4-8. PubMed ID: 22171470 [TBL] [Abstract][Full Text] [Related]
11. Comparison of the Efficacy of N9 Neuraminidase-Specific Monoclonal Antibodies against Influenza A(H7N9) Virus Infection. Wan H; Qi L; Gao J; Couzens LK; Jiang L; Gao Y; Sheng ZM; Fong S; Hahn M; Khurana S; Taubenberger JK; Eichelberger MC J Virol; 2018 Feb; 92(4):. PubMed ID: 29167344 [TBL] [Abstract][Full Text] [Related]
12. [Monoclonal antibodies in diseases of viral origin]. Aguilar Setién A; Kretschmer R Salud Publica Mex; 1985; 27(3):251-9. PubMed ID: 2996158 [No Abstract] [Full Text] [Related]
13. Comparison of antiviral activity between IgA and IgG specific to influenza virus hemagglutinin: increased potential of IgA for heterosubtypic immunity. Muramatsu M; Yoshida R; Yokoyama A; Miyamoto H; Kajihara M; Maruyama J; Nao N; Manzoor R; Takada A PLoS One; 2014; 9(1):e85582. PubMed ID: 24465606 [TBL] [Abstract][Full Text] [Related]
14. Human Anti-neuraminidase Antibodies Reduce Airborne Transmission of Clinical Influenza Virus Isolates in the Guinea Pig Model. Tan J; O'Dell G; Hernandez MM; Sordillo EM; Kahn Z; Kriti D; van Bakel H; Ellebedy AH; Wilson PC; Simon V; Krammer F; McMahon M J Virol; 2022 Jan; 96(2):e0142121. PubMed ID: 34669506 [TBL] [Abstract][Full Text] [Related]
15. Endogenous cytotoxic T-cell response contributes to the long-term antiretroviral protection induced by a short period of antibody-based immunotherapy of neonatally infected mice. Gros L; Pelegrin M; Michaud HA; Bianco S; Hernandez J; Jacquet C; Piechaczyk M J Virol; 2008 Feb; 82(3):1339-49. PubMed ID: 18032505 [TBL] [Abstract][Full Text] [Related]
16. An anti-H5N1 influenza virus FcDART antibody is a highly efficacious therapeutic agent and prophylactic against H5N1 influenza virus infection. Zanin M; Keck ZY; Rainey GJ; Lam CY; Boon AC; Rubrum A; Darnell D; Wong SS; Griffin Y; Xia J; Webster RG; Webby R; Johnson S; Foung S J Virol; 2015 Apr; 89(8):4549-61. PubMed ID: 25673719 [TBL] [Abstract][Full Text] [Related]
17. Airway Delivery of Anti-influenza Monoclonal Antibodies Results in Enhanced Antiviral Activities and Enables Broad-Coverage Combination Therapies. Vigil A; Frias-Staheli N; Carabeo T; Wittekind M J Virol; 2020 Oct; 94(22):. PubMed ID: 32847855 [TBL] [Abstract][Full Text] [Related]
18. Proteomics to study macrophage response to viral infection. Nyman TA; Matikainen S J Proteomics; 2018 May; 180():99-107. PubMed ID: 28647517 [TBL] [Abstract][Full Text] [Related]
19. Antibodies, viruses and vaccines. Burton DR Nat Rev Immunol; 2002 Sep; 2(9):706-13. PubMed ID: 12209139 [TBL] [Abstract][Full Text] [Related]
20. A crucial role for infected-cell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapy. Michaud HA; Gomard T; Gros L; Thiolon K; Nasser R; Jacquet C; Hernandez J; Piechaczyk M; Pelegrin M PLoS Pathog; 2010 Jun; 6(6):e1000948. PubMed ID: 20548955 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]